We have uncovered, and continue to catalogue, the "endotoxome": metabolites and metabolic intermediates normally produced during metabolism, that in excess have highly toxic properties. By exploiting the differences in metabolic activities between cancer and normal cells, we can strategically and selectively overload cancer cells with their own toxic metabolites as a therapeutic approach (publications). Additionally, we explore the notion that these toxic metabolites are playing hitherto unrecognized roles in diseases outside of cancer, such as in aging and neurodegenerative disorders.
